Navigation Links
New Research Study Seeks Improved Quality of Life for People in the Future with Schizophrenia

Miranda Chakos, MD of SUNY Downstate Medical Center leads research for local patients

Brooklyn, NY (PRWEB) August 26, 2008 -- Imagine going through the day without the ability to concentrate and focus on the things you enjoy and important tasks that you need to complete. Think what it would be like, struggling to remember what you just talked about or learned a short time ago. Consider how you would feel if you couldn't even accomplish simple tasks, such as making a phone call, grocery shopping or scheduling an appointment.

We all have challenging moments . . . but for people suffering from schizophrenia, these frustrations are a way of life, virtually every day. People with schizophrenia struggle to concentrate, remember and learn. These deficits associated with the thinking process are called cognitive impairments, making it difficult to accomplish the demands of everyday life, both big and small.

Managing the demands of daily life is made easier when individuals with schizophrenia maintain a stable regimen of medication -- even more so for those with trusted family members or caregivers to help oversee the individual's personal affairs and coordinate care. Despite the challenges, most people with schizophrenia and their caregivers are searching for a better quality of life.

Fortunately, there is hope, thanks to a new [investigational drug research study] now underway in the Brooklyn, NY area. The primary goal of this study is to evaluate the safety and effectiveness of an investigational drug in improving cognitive functioning for people with schizophrenia, using a new evaluation tool called [MATRICS] (Measurement and Treatment Research to Improve Cognition in Schizophrenia). This study is unique because participants are not required to change their already-stable medication regimen. Rather, the new investigational medication is added to their currently established treatment.

Candidates for this study must be 18 to 65 years old, diagnosed with schizophrenia at or before age 35 and currently taking one of five medications for schizophrenia which include olanzapine, risperidone/paliperidone, quetiapine or aripiprazole. Participants must also be considered outpatient (living in the community). [Qualified study participants] will receive all investigational medication and study-related care at no cost, and may also receive compensation for travel.

Miranda Chakos, MD of SUNY Downstate Medical Center seeks participants for this new study. If you or someone you know suffers from schizophrenia, please contact us for additional information at 888.988.6736. Further details about the study are also available at

Hal Coxon
Axiom Accelerated Clinical Patient Recruitment
(847) 919-1005

# # #

Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Research finds Americas elderly suffering abuse
2. Operations research promises continued gains for HIV treatment in resource-limited countries
3. SNM and ASTRO team up to advance molecular imaging and cancer research
4. CytoViva(R) Introduces Breakthrough Nano-Technology Research Tool
5. The Brain Aneurysm Foundation Announces 2008 Research Grant Recipients
6. Reeve Foundation Recruits Distinguished Stem-Cell Neurobiologist - The Salk Institutes Samuel L. Pfaff, Ph.D. - to its International Research Consortium
7. UTMB researchers test new vaccine to fight multiple influenza strains
8. AIAM Sponsors Leading Child Safety Research Initiative
9. UNC researcher aims to unmask cancer cells to trigger bodys immune system
10. STEMCELL Technologies Introduces AggreWell™400 for Standardized Embryonic Stem Cell and Induced Pluripotent Stem Cell Research
11. UCSF faculty receive $13.7M from CIRM for stem cell research
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today that ... Somu now offers travelers, value and care based Travel Services, including exclusive pricing ... well as, cabin upgrades and special amenities such as, shore excursions, discounted fares, ...
(Date:11/26/2015)... , ... November 26, 2015 , ... Jobs in hospital ... healthcare professionals and offered by healthcare staffing agency Aureus Medical Group . ... month of October 2015 among those searching for healthcare jobs through the company’s website, ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., the first ... annual Employee Benefits Conference. The Employee Benefits Conference was hosted by the International ... November 11th, 2015. The conference was held at the Hawaii Convention Center in ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... mental health and wellness consultation, has collaborated with Women’s Web – an ... reader’s queries on topics on mental and emotional well-being relationship, life balance, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional ... those found on mammography, according to a study published online in the journal ... seen on mammography may necessitate a change in treatment. , Breast MRI is ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 ... "Radioimmunoassay Market by Type (Reagents & ... Academics, Clinical Diagnostic Labs), Application (Research, Clinical ... 2020" report to their offering. ... addition of the "Radioimmunoassay Market by ...
(Date:11/25/2015)... ) ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
Breaking Medicine Technology: